MG
PLXP

Michael Gelband’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Michael Gelband’s Portfolio PLXP Stock Details PLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-16,758
Closed -$134K – 2812
2021
Q4 		$134K Buy
+16,758
New +$196K ﹤0.01% 1907

Other funds holding PLXP

MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Michael Gelband's PLXP Position: Q1 2022 in Review

Michael Gelband sold out of PLx Pharma Inc. Common Stock (PLXP) in Q1 2022, closing a stake of 16,758 shares — an estimated $134K sold.

Michael Gelband first reported a position in PLXP in Q4 2021 and held it in 1 quarter. The position peaked at $134K in Q4 2021. 50 funds tracked by Wall St. Rank hold PLXP as of Q1 2022.

  • Michael Gelband reported no remaining PLx Pharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Michael Gelband sold 16,758 PLx Pharma Inc. Common Stock shares in Q1 2022, an estimated $134K.
  • Michael Gelband first reported a position in PLx Pharma Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Michael Gelband's PLx Pharma Inc. Common Stock position peaked at $134K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.